Status:
COMPLETED
Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Glaucoma
Ocular Hypertension
Eligibility:
All Genders
Brief Summary
The objective of this Investigation is to evaluate the safety and efficacy of long-term treatment with Xalacom in medical practice. Also, occurrence of unknown and known adverse drug reactions (ADRs) ...
Detailed Description
All the patients whom an investigator prescribes the first Xalacom® should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the...
Eligibility Criteria
Inclusion
- Patients need to be administered Xalacom® in order to be enrolled in the surveillance.
Exclusion
- Patients not administered Xalacom®.
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
661 Patients enrolled
Trial Details
Trial ID
NCT01191008
Start Date
October 1 2010
End Date
May 1 2015
Last Update
June 1 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.